Scarica l'app Stockscreener
1.865
2.09%
-0.045
Inhibikase Therapeutics Inc Borsa (IKT) Ultime notizie
Inhibikase (NASDAQ: IKT) investors back 3M-share plan boost and officer protections - Stock Titan
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Price to sales forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Price to sales forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Price to earnings forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Price to book forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Inhibikase Therapeutics, Inc. Actuals & Estimates (NASDAQ:IKT) - TradingView
IKT Forecast — Price Target — Prediction for 2027 - TradingView
Inhibikase Therapeutics Inc (IKT) Institutional Confidence - TradingKey
Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibikase Therapeutics Inc (IKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Inhibikase Therapeutics Inc (IKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inhibikase Therapeutics Inc (IKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Inhibikase Therapeutics Inc (IKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inhibikase Therapeutics Inc (IKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibikase Therapeutics Inc (IKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibikase Therapeutics Inc (IKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inhibikase Therapeutics (IKT) Consolidates Near $1.67 – Key Levels in FocusTriple Bottom - newsline.com
IKT Initiates Coverage On Oppenheimer -- Rating Set to Outperfor - GuruFocus
Oppenheimer Initiates Inhibikase Therapeutics at Outperform - marketscreener.com
Inhibikase Therapeutics (IKT) Tests Support Zone After Slight DeclineFibonacci Entry Signals - newsline.com
IKT Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress ContinuesEarnings Recovery Stocks - newsline.com
Inhibikase Therapeutics (IKT) Edges Higher, Testing Key Resistance Amid Biotech Sector UncertaintyCTA Positioning - newsline.com
Inhibikase Therapeutics (IKT) Narrows Lower: Testing Key Support Near $1.61Size Factor - newsline.com
IKT Q1 2026 Earnings: Narrow EPS Beat as Clinical Pipeline Progress ContinuesQuarterly Financial Update - newsline.com
Inhibikase Therapeutics (IKT) Holds Near Support Amid Biotech Sector HeadwindsLiquidity Order Flow - newsline.com
Inhibikase Therapeutics (IKT) Recovers 3.5% as Buyers Defend Key Support LevelMAMA Signal - The Legal Advocate
Inhibikase Therapeutics (IKT) Holds Near Support Amid Narrow Trading RangeScalping Stock Signals - The Legal Advocate
H.C. Wainwright Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Pulmonary Arterial Hypertension Market Outlook Shows Strong Upward Trend at a CAGR of 6.7% During the Study Period (2022-2036) Supported by New Clinical Developments | DelveInsight - Fidelity
Inhibikase Therapeutics (IKT) Faces Selling Pressure as Stock Retreats to $1.69Parabolic SAR - Newser
Inhibikase Therapeutics (IKT) Q1 2026 Earnings: Narrowing Losses as Pipeline Progress Takes Center StageShared Momentum Picks - Newser
IKT SEC FilingsInhibikase Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Inhibikase Gains EU Clearance for Global PAH Trial - MyChesCo
Inhibikase Therapeutics, Inc. (IKT) Competitors - Meyka
IKT Stock Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 By Investing.com - Investing.com Nigeria
Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Cantor Fitzgerald Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 - Investing.com India
Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT) - The Globe and Mail
BofA Securities Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $6 - Moomoo
ADAR1 reports 9.9% stake in Inhibikase (NASDAQ: IKT) via managed accounts - Stock Titan
Trails Edge holds 8.06M Inhibikase shares — Trails Edge (NASDAQ: IKT) - Stock Titan
Commodore Capital (IKT) reports 14.05M shares equivalent, 9.9% cap - Stock Titan
Perceptive Advisors/Perceptive Life Sciences disclose 8.9% holding in IKT (IKT) - Stock Titan
Maxim Group Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Inhibikase Therapeutics, Inc.Common Stock (NQ: IKT - FinancialContent
0.46%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):